[EFFECT] NLS Pharmaceutics Ltd. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

11/19/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	November 18, 2025

Accession Number:

0001213900-25-106799

Submission Type:

POS AM

CIK:	0001783036
Company Name:	NewcelX Ltd.
File Number:	333-284075

Source: View Original Filing on SEC EDGAR

Nls Pharmaceutics Ltd

NASDAQ:NLSP

NLSP Rankings

#6700 Ranked by Market Cap

N/A Ranked by Dividends

NLSP Latest News

Nov 17, 2025

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

Oct 30, 2025

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

Oct 29, 2025

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

Oct 29, 2025

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

Oct 29, 2025

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLSP Latest SEC Filings

Nov 19, 2025

[EFFECT] NLS Pharmaceutics Ltd. SEC Filing

Nov 17, 2025

[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)

Nov 7, 2025

[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)

Nov 5, 2025

[POS AM] NLS Pharmaceutics Ltd. SEC Filing

Nov 4, 2025

[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)

NLSP Stock Data

Market Cap 3.97M

Float 3.08M

Insiders Ownership 32.46%

Institutions Ownership 9.81%

Short Percent 0.51%

Industry Biotechnology

Sector Healthcare

Website Link

Country Switzerland

City Zurich